SCHEMBL688176

SCHEMBL688176

N#Cc1ccccc1Cn1ccc2oc(=O)[nH]c2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.42
ALDH1A1 P00352 9/20 0.41
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TSHR P16473 4/20 0.39
KDM4E B2RXH2 3/20 0.38
GALR3 O60755 1/20 0.38
RAB9A P51151 1/20 0.38
NOX4 Q9NPH5 1/20 0.38
TP53 P04637 1/20 0.36
MCL1 Q07820 1/20 0.36
NPSR1 Q6W5P4 4/20 0.36
HPGD P15428 3/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687633 0.81 ALDH1A1 (0.42) ALDH1A1MAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL688408 0.81 THRB (0.47) ALDH1A1MAPTSMN1; SMN2KDM4ETP53
SCHEMBL687519 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL687826 0.81 POLB (0.49) ALDH1A1MAPTSMN1; SMN2TSHRKDM4E
SCHEMBL686785 0.81 HDAC3 (0.41) CYP19A1ALDH1A1TSHRKDM4EMCL1
SCHEMBL687397 0.78 MCL1 (0.36) ALDH1A1KDM4EMCL1GAALMNA
SCHEMBL687698 0.78 LMNA (0.51) ALDH1A1KMT2AMEN1HSD17B10LMNA
SCHEMBL687704 0.78 ADORA2A (0.38) ALDH1A1KDM4EMCL1NPSR1KMT2A
SCHEMBL688361 0.78 MAPK14 (0.43) ALDH1A1SMN1; SMN2KDM4ETP53MCL1
SCHEMBL686853 0.77 MCL1 (0.35) MCL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. 2004-04-01 US claimed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP claimed
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. 2004-04-01 US disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 CYP19A1 4352/4885ALDH1A1 53/4885MAPT 2314/4885
US-20040063955-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, FN1 CYP19A1 4386/4885ALDH1A1 57/4885MAPT 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.